Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835919 Phase 1 in healthy adults
NCT02974374Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing PF-06835919 with Placebo (2 arms). Primary endpoint: Number of Subjects experiencing an Adverse Event. Started Oct 2016; status: completed.
02
Drugs
PF-06835919
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02974374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974374.